Asian Patent Acceptances Enhance Braasch Biotech Livestock Portfolio

Minneapolis, MN, January 21, 2016 --(PR.com)-- Braasch Biotech LLC, a biopharmaceutical company developing and commercializing anti-somatostatin vaccines, today updated its patent acceptances in Asia to include, Viet Nam, South Korea, China, Japan and The Philippines. The patents cover the use of Braasch’s product candidate, JH14-Somatovac® for increasing livestock productivity. Braasch’s vaccines are directed toward the archetype counter-regulatory hormone somatostatin. The effects of attenuating somatostatin levels by Braasch vaccines have resulted in increased efficiencies both in milk yields in dairy cows and lean meat production in pigs.

With international agencies and consumers banning animal proteins containing growth-enhancing drugs, such as ractopamine and recombinant bovine somatotropin, new initiatives will be required to enhance the sustainability of animal protein production without proportionally increasing land for agriculture.

“Braasch vaccines allow a safe method to encourage treated animals to achieve their own endogenous ability to be more productive,” stated Jeralyn Haffer, Braasch Biotech’s CEO. “The primary goal of our vaccines is to safely improve the protein production of farmed animals without the use of exogenous promoters, to meet enhanced world demand for animal-derived protein. Equally important to us is that productivity enhancement, as well as environmental and human protection, are cornerstones of our vaccine technology.”

Braasch Biotech’s current livestock enhancement portfolio already includes granted patents in the United States, European Union, Russia, Latin America, Israel, South Africa, Australia and New Zealand. Braasch continues to pursue patent applications in multiple worldwide jurisdictions for its new technologies.

About Braasch Biotech
Braasch Biotech has pioneered a new field of metabolic and therapeutic vaccine approaches utilizing its Somatovac® technologies. The company has received numerous US and International patents for vaccine usage in livestock productivity and obesity. Braasch Biotech is a privately held biopharmaceutical company with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com